Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Mereo BioPharma Group (MREO) Accumulated Depreciation & Amortization: 2022-2025

Historic Accumulated Depreciation & Amortization for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $1.0 million.

  • Mereo BioPharma Group's Accumulated Depreciation & Amortization rose 8.61% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 18.55%. This contributed to the annual value of $949,000 for FY2024, which is 18.63% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's Accumulated Depreciation & Amortization stood at $1.0 million, which was down 5.68% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Accumulated Depreciation & Amortization peaked at $1.1 million during Q2 2025, and registered a low of $736,000 during Q4 2022.
  • In the last 3 years, Mereo BioPharma Group's Accumulated Depreciation & Amortization had a median value of $956,500 in 2024 and averaged $949,875.
  • Data for Mereo BioPharma Group's Accumulated Depreciation & Amortization shows a peak YoY increased of 26.57% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Mereo BioPharma Group's Accumulated Depreciation & Amortization stood at $736,000 in 2022, then grew by 8.70% to $800,000 in 2023, then rose by 18.63% to $949,000 in 2024, then climbed by 8.61% to $1.0 million in 2025.
  • Its Accumulated Depreciation & Amortization was $1.0 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.0 million in Q1 2025.